Literature DB >> 11796730

Crystal structure of the productive ternary complex of dihydropyrimidine dehydrogenase with NADPH and 5-iodouracil. Implications for mechanism of inhibition and electron transfer.

Doreen Dobritzsch1, Stefano Ricagno, Gunter Schneider, Klaus D Schnackerz, Ylva Lindqvist.   

Abstract

Dihydroprymidine dehydrogenase catalyzes the first and rate-limiting step in pyrimidine degradation by converting pyrimidines to the corresponding 5,6- dihydro compounds. The three-dimensional structures of a binary complex with the inhibitor 5-iodouracil and two ternary complexes with NADPH and the inhibitors 5-iodouracil and uracil-4-acetic acid were determined by x-ray crystallography. In the ternary complexes, NADPH is bound in a catalytically competent fashion, with the nicotinamide ring in a position suitable for hydride transfer to FAD. The structures provide a complete picture of the electron transfer chain from NADPH to the substrate, 5-iodouracil, spanning a distance of 56 A and involving FAD, four [Fe-S] clusters, and FMN as cofactors. The crystallographic analysis further reveals that pyrimidine binding triggers a conformational change of a flexible active-site loop in the alpha/beta-barrel domain, resulting in placement of a catalytically crucial cysteine close to the bound substrate. Loop closure requires physiological pH, which is also necessary for correct binding of NADPH. Binding of the voluminous competitive inhibitor uracil-4-acetic acid prevents loop closure due to steric hindrance. The three-dimensional structure of the ternary complex enzyme-NADPH-5-iodouracil supports the proposal that this compound acts as a mechanism-based inhibitor, covalently modifying the active-site residue Cys-671, resulting in S-(hexahydro-2,4-dioxo-5-pyrimidinyl)cysteine.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11796730     DOI: 10.1074/jbc.M111877200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

1.  A hidden metabolic pathway exposed.

Authors:  Andrei Osterman
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-04       Impact factor: 11.205

2.  Reverse screening approach to identify potential anti-cancer targets of dipyridamole.

Authors:  Shu-Min Ge; Dong-Ling Zhan; Shu-Hua Zhang; Li-Qiang Song; Wei-Wei Han
Journal:  Am J Transl Res       Date:  2016-12-15       Impact factor: 4.060

3.  Gene-Specific Variant Classifier (DPYD-Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase.

Authors:  Shikshya Shrestha; Cheng Zhang; Calvin R Jerde; Qian Nie; Hu Li; Steven M Offer; Robert B Diasio
Journal:  Clin Pharmacol Ther       Date:  2018-02-02       Impact factor: 6.875

4.  Insights into Flavin-based Electron Bifurcation via the NADH-dependent Reduced Ferredoxin:NADP Oxidoreductase Structure.

Authors:  Julius K Demmer; Haiyan Huang; Shuning Wang; Ulrike Demmer; Rudolf K Thauer; Ulrich Ermler
Journal:  J Biol Chem       Date:  2015-07-02       Impact factor: 5.157

Review 5.  Bioinformatics and variability in drug response: a protein structural perspective.

Authors:  Jennifer L Lahti; Grace W Tang; Emidio Capriotti; Tianyun Liu; Russ B Altman
Journal:  J R Soc Interface       Date:  2012-05-02       Impact factor: 4.118

6.  Genetic variations and haplotype structures of the DPYD gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences.

Authors:  Keiko Maekawa; Mayumi Saeki; Yoshiro Saito; Shogo Ozawa; Kouichi Kurose; Nahoko Kaniwa; Manabu Kawamoto; Naoyuki Kamatani; Ken Kato; Tetsuya Hamaguchi; Yasuhide Yamada; Kuniaki Shirao; Yasuhiro Shimada; Manabu Muto; Toshihiko Doi; Atsushi Ohtsu; Teruhiko Yoshida; Yasuhiro Matsumura; Nagahiro Saijo; Jun-Ichi Sawada
Journal:  J Hum Genet       Date:  2007-09-09       Impact factor: 3.172

7.  Induced fit in guanidino kinases--comparison of substrate-free and transition state analog structures of arginine kinase.

Authors:  Mohammad S Yousef; Shawn A Clark; Pamela K Pruett; Thayumanasamy Somasundaram; W Ross Ellington; Michael S Chapman
Journal:  Protein Sci       Date:  2003-01       Impact factor: 6.725

8.  Hypermutation of DPYD Deregulates Pyrimidine Metabolism and Promotes Malignant Progression.

Authors:  Lauren Edwards; Rohit Gupta; Fabian Volker Filipp
Journal:  Mol Cancer Res       Date:  2015-11-25       Impact factor: 5.852

9.  Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity.

Authors:  Steven M Offer; Croix C Fossum; Natalie J Wegner; Alexander J Stuflesser; Gabriel L Butterfield; Robert B Diasio
Journal:  Cancer Res       Date:  2014-03-19       Impact factor: 12.701

10.  Molecular evolution of dihydrouridine synthases.

Authors:  Joanna M Kasprzak; Anna Czerwoniec; Janusz M Bujnicki
Journal:  BMC Bioinformatics       Date:  2012-06-28       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.